Covista (CVSA)

Consumer Defensive · Education & Training Services
$129.38 -0.70% on the day Market cap $4.4B 52-week range $86.97 to $156.26 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
-3% a year for 10 years

At a market value of $4.4B, Covista's free cash flow of $393M (fiscal 2026) would need to grow about -3% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Covista's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price-2.7% a year
Free cash flow, last 9 years8.5% a year
Revenue, same period32.8% a year
Price to free cash flow11.1x

Fundamental grade

B

Five factors scored 1 to 9 from CVSA's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation7
Profitability7
Growth7
Financial health3
Cash efficiency9

Results from SEC filings

Fiscal years, from Covista's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20222023202420252026
Revenue$1.4B$1.5B$1.6B$1.8B$2.0B
Net income$311M$93M$137M$237M$252M
Free cash flow-$20M$166M$247M$288M$393M
EPS (diluted)$6.43$2.05$3.39$6.18$7.04
Operating margin5.6%11.6%13.7%19.1%19.6%

Where the revenue comes from

Revenue by segments, fiscal 2026. Every breakdown, year by year.

Walden$805M41%
Chamberlain$750M38%
Medical and Veterinary$399M20%

Superinvestors who own CVSA

From each investor's latest 13F filing (what a 13F shows). 4 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
John Rogers
Ariel Investments
Trimmed $221M2.2%Q2 2026
Charles de Vaulx
International Value Advisers
Trimmed $38M6.1%Q4 2020
Cliff Asness
AQR Capital Management
Trimmed $33M0.01%Q2 2026
Joel Greenblatt
Gotham Asset Management
Trimmed $2M0.00%Q2 2026

Insider buying

Open-market purchases by Covista's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you. Every purchase since records began.

DateInsiderSharesPriceValue
Mar 11, 2026 Michael W Malafronte
8,890$100.94$897,357
Mar 10, 2026 Michael W Malafronte
11,841$100.86$1M
Mar 10, 2026 Michael W Malafronte
15,305$100.86$2M
Mar 3, 2026 Michael W Malafronte
1,200$97.97$117,564

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when CVSA trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Covista's stock price imply?

At a market value of $4.4B, Covista would need its free cash flow to grow about -3% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 9% a year.

Are Covista insiders buying the stock?

4 open-market insider purchases of CVSA in the last 12 months, from SEC Form 4 filings.

Which superinvestors own Covista?

4 of the superinvestors Investingly tracks hold CVSA in their latest 13F, including John Rogers, Charles de Vaulx, Cliff Asness.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.